Globus Medical, Inc. (NYSE:GMED) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Globus Medical, Inc. (NYSE:GMED) has been assigned a consensus recommendation of “Moderate Buy” from the seventeen ratings firms that are currently covering the company, Marketbeat Ratings reports. Five investment analysts have rated the stock with a hold recommendation, nine have issued a buy recommendation and three have issued a strong buy recommendation on the company. The average 1-year price target among analysts that have issued a report on the stock in the last year is $101.7692.

A number of equities research analysts have weighed in on GMED shares. BMO Capital Markets initiated coverage on shares of Globus Medical in a report on Wednesday, July 8th. They set an “outperform” rating and a $94.00 target price on the stock. Wall Street Zen lowered shares of Globus Medical from a “strong-buy” rating to a “buy” rating in a report on Saturday, May 9th. Royal Bank Of Canada cut their price target on shares of Globus Medical from $120.00 to $115.00 and set an “outperform” rating on the stock in a report on Monday, July 13th. Piper Sandler reduced their price objective on shares of Globus Medical from $115.00 to $100.00 and set an “overweight” rating on the stock in a research note on Monday, June 15th. Finally, UBS Group initiated coverage on Globus Medical in a report on Tuesday, July 28th. They issued a “neutral” rating and a $82.00 price objective for the company.

Insider Activity at Globus Medical

In other Globus Medical news, Director David D. Davidar sold 25,000 shares of the company’s stock in a transaction dated Friday, June 5th. The stock was sold at an average price of $80.76, for a total value of $2,019,000.00. Following the sale, the director owned 510,175 shares in the company, valued at approximately $41,201,733. The trade was a 4.67% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Company insiders own 18.38% of the company’s stock.

Hedge Funds Weigh In On Globus Medical

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. American Capital Management Inc. bought a new stake in Globus Medical in the second quarter valued at approximately $51,599,000. Paradigm Capital Management Inc. NY acquired a new stake in Globus Medical during the 2nd quarter valued at approximately $70,042,000. Globeflex Capital L P bought a new position in Globus Medical during the 2nd quarter worth approximately $474,000. Annex Advisory Services LLC raised its holdings in Globus Medical by 6.4% during the 2nd quarter. Annex Advisory Services LLC now owns 372,794 shares of the medical device company’s stock worth $29,454,000 after purchasing an additional 22,407 shares during the last quarter. Finally, Handelsbanken Fonder AB lifted its position in shares of Globus Medical by 5.3% in the 2nd quarter. Handelsbanken Fonder AB now owns 43,897 shares of the medical device company’s stock worth $3,468,000 after purchasing an additional 2,200 shares during the period. 95.16% of the stock is owned by institutional investors and hedge funds.

Globus Medical Trading Down 0.2%

Globus Medical stock opened at $85.75 on Monday. The stock has a 50-day moving average price of $79.98 and a two-hundred day moving average price of $84.90. Globus Medical has a 12 month low of $54.15 and a 12 month high of $101.40. The company has a market capitalization of $11.51 billion, a PE ratio of 21.93, a P/E/G ratio of 1.38 and a beta of 0.95.

Globus Medical (NYSE:GMED) last released its quarterly earnings results on Thursday, August 6th. The medical device company reported $1.34 earnings per share for the quarter, topping the consensus estimate of $1.10 by $0.24. Globus Medical had a return on equity of 14.57% and a net margin of 17.02%.The company had revenue of $789.61 million for the quarter, compared to analysts’ expectations of $782.88 million. During the same period in the previous year, the business posted $0.86 earnings per share. The business’s quarterly revenue was up 5.9% compared to the same quarter last year. Globus Medical has set its FY 2026 guidance at 4.950-5.050 EPS. As a group, analysts predict that Globus Medical will post 4.99 earnings per share for the current fiscal year.

Globus Medical Company Profile

Globus Medical, Inc (NYSE:GMED) is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.